|
gptkbp:instanceOf
|
gptkb:drug
biologic medication
|
|
gptkbp:administeredBy
|
gptkb:physician
|
|
gptkbp:approvalYear
|
2005
2010
|
|
gptkbp:approvedBy
|
gptkb:Japan
|
|
gptkbp:ATCCode
|
L04AC07
|
|
gptkbp:CASNumber
|
375823-41-9
|
|
gptkbp:chemicalFormula
|
C6428H9976N1720O2018S42
|
|
gptkbp:contraindication
|
active serious infection
|
|
gptkbp:genericName
|
gptkb:tocilizumab
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Actemra
|
|
gptkbp:indication
|
gptkb:juvenile_idiopathic_arthritis
gptkb:COVID-19_(severe_cases)
gptkb:giant_cell_arteritis
rheumatoid arthritis
cytokine release syndrome
|
|
gptkbp:KEGGID
|
D08952
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Genentech
gptkb:Roche
|
|
gptkbp:marketedAs
|
gptkb:RoActemra_(Europe)
|
|
gptkbp:mechanismOfAction
|
IL-6 receptor antagonist
|
|
gptkbp:monitors
|
liver function
blood counts
lipid levels
|
|
gptkbp:monoclonalAntibodyType
|
humanized
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
adults
children (certain indications)
|
|
gptkbp:prescriptionRequired
|
https://www.gene.com/download/pdf/actemra_prescribing.pdf
|
|
gptkbp:PubChem_CID
|
11449216
DB06273
|
|
gptkbp:riskFactor
|
hypersensitivity reactions
serious infections
gastrointestinal perforation
liver injury
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
headache
hypertension
infections
elevated liver enzymes
neutropenia
|
|
gptkbp:target
|
gptkb:interleukin-6_receptor
|
|
gptkbp:UNII
|
QY5YJ51W8W
|
|
gptkbp:usedDuringCOVID19Pandemic
|
yes
|
|
gptkbp:usedInTreatmentOf
|
autoimmune diseases
|
|
gptkbp:bfsParent
|
gptkb:Roche
gptkb:Chugai_Pharmaceutical
|
|
gptkbp:bfsLayer
|
6
|